122 related articles for article (PubMed ID: 38303291)
1. [Tolerability and Outcome of Neoadjuvant GS Therapy for Resectable Pancreatic Cancer].
Yamashita M; Shimizu J; Sato Y; Noma T; Hagihara K; Yanagimoto Y; Suzuki Y; Ikenaga M; Kawase T; Imamura H; Akagi K; Iwasawa S; Tomita N
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1411-1413. PubMed ID: 38303291
[TBL] [Abstract][Full Text] [Related]
2. The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer.
Takeda T; Sasaki T; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Jpn J Clin Oncol; 2021 Apr; 51(4):604-611. PubMed ID: 33479765
[TBL] [Abstract][Full Text] [Related]
3. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
Motoi F; Satoi S; Honda G; Wada K; Shinchi H; Matsumoto I; Sho M; Tsuchida A; Unno M;
J Gastroenterol; 2019 Feb; 54(2):194-203. PubMed ID: 30182219
[TBL] [Abstract][Full Text] [Related]
4. Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery.
Kitano Y; Inoue Y; Takeda T; Oba A; Ono Y; Sato T; Ito H; Ozaka M; Sasaki T; Sasahira N; Baba H; Takahashi Y
Ann Surg Oncol; 2023 Aug; 30(8):5093-5102. PubMed ID: 37140750
[TBL] [Abstract][Full Text] [Related]
5. A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer.
Okano N; Matsuki R; Toki M; Gondo K; Ochiai K; Watanabe S; Tateishi H; Kogure M; Suzuki Y; Sugiyama M; Nagashima F; Shibahara J; Sakamoto Y; Furuse J
Intern Med; 2023 Feb; 62(3):327-334. PubMed ID: 35793961
[TBL] [Abstract][Full Text] [Related]
6. Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Nakagawa N; Takahashi S; Sueda T
Cancer Chemother Pharmacol; 2017 Jan; 79(1):37-47. PubMed ID: 27878355
[TBL] [Abstract][Full Text] [Related]
7. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.
Kim EJ; Ben-Josef E; Herman JM; Bekaii-Saab T; Dawson LA; Griffith KA; Francis IR; Greenson JK; Simeone DM; Lawrence TS; Laheru D; Wolfgang CL; Williams T; Bloomston M; Moore MJ; Wei A; Zalupski MM
Cancer; 2013 Aug; 119(15):2692-700. PubMed ID: 23720019
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
Motoi F; Ishida K; Fujishima F; Ottomo S; Oikawa M; Okada T; Shimamura H; Takemura S; Ono F; Akada M; Nakagawa K; Katayose Y; Egawa S; Unno M
Ann Surg Oncol; 2013 Nov; 20(12):3794-801. PubMed ID: 23838925
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer.
Saito K; Isayama H; Sakamoto Y; Nakai Y; Ishigaki K; Tanaka M; Watadani T; Arita J; Takahara N; Mizuno S; Kogure H; Ijichi H; Tateishi K; Tada M; Hasegawa K; Fukayama M; Kokudo N; Koike K
Med Oncol; 2018 May; 35(7):100. PubMed ID: 29846849
[TBL] [Abstract][Full Text] [Related]
10. A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma.
Furukawa T; Sasaki T; Ono Y; Kawano F; Takamatsu M; Mori C; Mie T; Yamada Y; Okamoto T; Takeda T; Kasuga A; Matsuyama M; Ozaka M; Takahashi Y; Sasahira N
Clin J Gastroenterol; 2021 Oct; 14(5):1571-1577. PubMed ID: 34255287
[TBL] [Abstract][Full Text] [Related]
11. Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors.
Masui T; Doi R; Kawaguchi Y; Sato A; Nakano K; Ito T; Anazawa T; Takaori K; Uemoto S
Surg Today; 2016 Nov; 46(11):1282-9. PubMed ID: 26860274
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015).
Yamada D; Kobayashi S; Takahashi H; Akita H; Yamada T; Asaoka T; Shimizu J; Takeda Y; Yokoyama S; Tsujie M; Tomokuni A; Tanemura M; Morimoto O; Murakami M; Kim Y; Nakahira S; Hama N; Sugimoto K; Hashimoto K; Doki Y; Eguchi H
Trials; 2021 Aug; 22(1):568. PubMed ID: 34446057
[TBL] [Abstract][Full Text] [Related]
13. Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer.
Okada KI; Hirono S; Kawai M; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Hayami S; Yamaue H
Anticancer Res; 2017 Feb; 37(2):853-858. PubMed ID: 28179342
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma.
Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
Pancreas; 2021 May-Jun 01; 50(5):744-750. PubMed ID: 34016892
[TBL] [Abstract][Full Text] [Related]
16. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
17. Incidence and Risk of Venous Thromboembolism in Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy.
Kamiya M; Kawahara S; Kamioka Y; Murakawa M; Aoyama T; Kobayashi S; Ueno M; Yamamoto N; Oshima T; Yukawa N; Rino Y; Masuda M; Morinaga S
Anticancer Res; 2023 Apr; 43(4):1741-1747. PubMed ID: 36974795
[TBL] [Abstract][Full Text] [Related]
18. Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multicenter Phase II Trial (NAC-GA Trial).
Okada KI; Shimokawa T; Hirono S; Kawai M; Sho M; Satoi S; Matsumoto I; Eguchi H; Murakami Y; Yamada S; Doi M; Yamaue H;
Oncology; 2017; 93(5):343-346. PubMed ID: 28719890
[TBL] [Abstract][Full Text] [Related]
19. Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma.
Matsuyama R; Mori R; Ota Y; Homma Y; Yabusita Y; Hiratani S; Murakami T; Sawada Y; Miyake K; Shimizu Y; Kumamoto T; Endo I
Ann Surg Oncol; 2022 Apr; 29(4):2393-2405. PubMed ID: 34994885
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
Nagakawa Y; Hosokawa Y; Nakayama H; Sahara Y; Takishita C; Nakajima T; Hijikata Y; Kasuya K; Katsumata K; Tokuuye K; Tsuchida A
Cancer Chemother Pharmacol; 2017 May; 79(5):951-957. PubMed ID: 28378027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
